
Case Study of the impact of the drug on COVID 19 Patients :
Recently, a French lab followed 80 patients who received a combination of hydroxychloroquine and azithromycin. Except for an 86-year-old patient who died and a 74-year-old patient who is still under intensive care, all the patients demonstrated improvement.
The sample size of the study is small enough to be what Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Disease, called “anecdotal evidence”. Second, the fact that everybody but the elderly recovered may be because the elderly were more vulnerable to COVID-19 and that the younger patients were more likely to recover anyway.
According to the authors of this study, so far, 503 patients have undergone the same treatment, and only one patient has succumbed to COVID-19. However, there is no further information as to if this study is separate or different from the published study.
Around the same time, a New York family physician, who claimed in media interviews, without the support of a peer-reviewed publication, that he had treated 699 COVID-19 patients with the same regiment to the result of zero deaths and only a few hospitalizations. The entire exercise could not be classified as a rigorous designed and tested clinical trial because there was not a control group of patients who did not receive the drug, for comparison in efficacy. In other words, without a no-drug control group, it will be impossible to distinguish the drug-related recovery of patient in the drugged group from the patients who recover even in the absence of the medication.
Most of the people who went to the doctor had mild symptoms, to begin with; otherwise, they would have gone to the emergency room. As more than 95% of the COVID-19 cases are mild, most of the patients who went to see the doctor were going to recover anyway. Lastly, the doctor treated the so-called coronavirus patients before testing became widely available. Therefore, it is unclear how many of the patients were infected with SARC-CoV-2.
Ref Credit and Source of Information technologynetworks.com